Latest News
Inhalon Biopharma Announces Poster Presentation at Military Health System Research Symposium 2024
​
​
​Durham, North Carolina, August 26, 2024 — Inhalon Biopharma (Inhalon), a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced plans to present the results of its Phase 1b study at the Military Health System Research Symposium (MHSRS) that will take place August 26-29, 2024, in Kissimmee, Florida.
​
Inhalon Biopharma is developing inhaled antibody products as potential treatments for a range of acute respiratory infections such as respiratory syncytial virus (RSV), SARS-CoV-2, metapneumovirus (hMPV), and influenza. This treatment approach involves the delivery of antibody therapy directly to the site of infection in the airways, using a handheld nebulizer rather than a systemic administration via an oral or intravenous delivery approach. Such a treatment approach is believed to be more effective, reduce costs and ease the burden of care on patients and the health care system.
The conference presentation will share results from a U.S. Army Medical Research and Development Command (USAMRDC) and Medical Technology Enterprise Consortium (MTEC) funded study which evaluated the distribution and safety of Inhalon’s IN-006, a nebulized anti-SARS-CoV-2 monoclonal antibody for treatment of COVID-19, to demonstrate the ease and efficacy of this treatment approach for ARIs.
“Our military personnel are particularly vulnerable to respiratory infections due to their close living conditions and the unique job-related stresses they face. Historically, antibody-based treatments for respiratory infections have been administered with costly systemic dosing regimens, largely via intravenous methods requiring healthcare worker supervision. Through our research, we have shown that nebulized antibodies offer a potentially more effective, self-administered alternative that may substantially reduce the burden of addressing respiratory infections both on military and civilian healthcare infrastructure,” said John Whelan, president and CEO at Inhalon Biopharma.
Presentation Details
Session Title: Update in Emerging Infectious Diseases of Military Importance: Predicting and Preventing Future Outbreaks in Military Settings
Poster Title: Nebulization Provides Superior Delivery of an Antiviral Monoclonal Antibody Compared to Intravenous Infusion
Session Date & Time: August 28, 2024, 10 a.m.
Session Title: Update in Emerging Infectious Diseases of Military Importance: Predicting and Preventing Future Outbreaks in Military Settings
Poster Title: Development of an Antibody Fusion Protein as a Pan-Variant, Warfighter-Friendly, Decoy Therapeutic to Address Outbreaks with Pandemic Potential
Session Date & Time: August 28, 2024, 10 a.m.
About Inhalon Biopharma
Inhalon Biopharma is a private, clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes approved U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Cambrian Growth Partners, Berkeley Catalyst Fund, JSR Life Sciences and Life Science Angels, as well as several federal grants from the NIH and USAMRDC.
About U.S. Army Medical Research and Development Command
The U.S. Army Medical Research and Development Command is the Army's medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical and biological defense. https://mrdc.health.mil/.
About MTEC
The Medical Technology Enterprise Consortium is a 501(c)(3) biomedical technology consortium that is internationally-dispersed, collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement with the U.S. Army Medical Research and Development Command. The consortium focuses on the development of medical solutions that protect, treat, and optimize the health and performance of U.S. military personnel and civilians. To find out more about MTEC, visit https://mtec-sc.org/.
​​
Contact
​
For General Inquires
John Whelan
Media
Gwen Gordon
​​